DE69911944D1 - Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins - Google Patents

Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins

Info

Publication number
DE69911944D1
DE69911944D1 DE69911944T DE69911944T DE69911944D1 DE 69911944 D1 DE69911944 D1 DE 69911944D1 DE 69911944 T DE69911944 T DE 69911944T DE 69911944 T DE69911944 T DE 69911944T DE 69911944 D1 DE69911944 D1 DE 69911944D1
Authority
DE
Germany
Prior art keywords
compositions
extending
effect
clostridium neurotoxin
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69911944T
Other languages
English (en)
Other versions
DE69911944T2 (de
Inventor
Oliver Dolly
Roger Aoki
Paiva Anton De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE69911944D1 publication Critical patent/DE69911944D1/de
Application granted granted Critical
Publication of DE69911944T2 publication Critical patent/DE69911944T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69911944T 1998-04-29 1999-04-15 Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins Expired - Fee Related DE69911944T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8347298P 1998-04-29 1998-04-29
US83472P 1998-04-29
PCT/US1999/008303 WO1999055359A1 (en) 1998-04-29 1999-04-15 Compositions and methods for extending the action of clostridial neurotoxin

Publications (2)

Publication Number Publication Date
DE69911944D1 true DE69911944D1 (de) 2003-11-13
DE69911944T2 DE69911944T2 (de) 2004-07-22

Family

ID=22178574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69911944T Expired - Fee Related DE69911944T2 (de) 1998-04-29 1999-04-15 Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins

Country Status (10)

Country Link
US (1) US20040228881A1 (de)
EP (1) EP1073455B1 (de)
JP (2) JP2002512977A (de)
AT (1) ATE251463T1 (de)
AU (1) AU3748499A (de)
CA (1) CA2328111A1 (de)
DE (1) DE69911944T2 (de)
ES (1) ES2207208T3 (de)
HK (1) HK1032752A1 (de)
WO (1) WO1999055359A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870464A3 (de) * 1999-06-02 2008-03-12 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20030162700A1 (en) * 2000-03-03 2003-08-28 Shipham Kylie Ann-Maree Method of treatment
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110243899A1 (en) * 2008-04-25 2011-10-06 National University Corporation Chiba University Wnt Signaling Inhibitor Comprising Insulin-Like Growth Factor-Binding Protein
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
AU6808001A (en) * 2000-05-23 2001-12-03 Neurologix Inc Glutamic acid decarboxylase (gad) based delivery systems

Also Published As

Publication number Publication date
CA2328111A1 (en) 1999-11-04
HK1032752A1 (en) 2001-08-03
EP1073455A1 (de) 2001-02-07
ATE251463T1 (de) 2003-10-15
ES2207208T3 (es) 2004-05-16
JP2006063085A (ja) 2006-03-09
AU3748499A (en) 1999-11-16
EP1073455B1 (de) 2003-10-08
US20040228881A1 (en) 2004-11-18
DE69911944T2 (de) 2004-07-22
WO1999055359A1 (en) 1999-11-04
JP2002512977A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
DE69911944D1 (de) Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins
BR9608402A (pt) Oligonucleotìdeo anti-sentido, e, processos para inibição da expressão do raf humano, da hiperproliferação de células e para tratamento da condição proliferativa anormal.
DE69728782D1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
EA199700225A1 (ru) Способ предотвращения и лечения сенсорно-невральной тугоухости и вестибулярных нарушений с помощью белкового продукта нейротрофического фактора глиальной клеточной линии (gdnf)
DE69835846D1 (de) Modifizierte hydrogenierte Polymere, Verfahren und Verwendung
DE69911108D1 (de) Apparat zum Behandlung von Bekleidungsstücken
DE69840987D1 (de) Physikalischer Zufallszahlengenerator, Verfahren zum Generieren von physikalischen Zufallszahlen und Speichermedium für physikalische Zufallszahlen
DE69715325D1 (de) Apparat zum Behandlung von Bekleidungsstücken
ATE317226T1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
FR2757163B1 (fr) Nouveaux derives insolubles de s-triazine, leur procede de preparation, compositions les contenant et leurs utilisations
DE60036486D1 (de) Methode und apparat zum prüfen von musterübereinstimmungen
DE69431643T2 (de) Vorrichtung und Verfahren zum Herstellen von bei hohen Temperaturen leit- und widerstandsfähigen Beschichtungen, Mittel und Gegenstand
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
WO2002020846A3 (en) Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DK1003865T3 (da) Mutation i Connexin 26 genet ansvarlig for prelingual non-syndromisk dövhed og fremgangsmåde til detektering
DE69911986D1 (de) Einrichtung und verfahren zum ausgleichen und verteilen von steueralgorithmenlasten
WO2000018801A3 (en) Ncam binding compounds
SE9503117L (sv) Ny användning av padlockprober
ATE291080T1 (de) Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
ATE263239T1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
ATE312175T1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
DE69909890D1 (de) Trommel zum Walken, Färben und Gerben

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee